CIBI322A102: A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors

About this Study

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of IBI322 in cancer patients who failed standard treatment.

Sponsor Protocol ID:CIBI322A102
IRB Number:2020-0283
Actively Enrolling
Interventional
Phase 1
June 30, 2022
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Histologically/cytologically confirmed unresectable or metastatic solid tumors or relapsed/recurrent lymphomas for which there is not not available treatment
  • Male or femaleĀ 
  • 18 years of age or older

Exclusion Criteria
  • Previous exposure to any anti-CD47 monoclonal antibody, SIRP antibody, or CD47/SIRP recombinant protein
  • Participating in another interventional clinical study
  • On blood thinners and/or require concomitant aspirin or other nonsteroids anti-inflammatory medications
  • History of blood transfusions within 2 week prior to screening, or use of erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), thrombopoietin (TPO) or IL-11 therapy
  • Whole pelvic radiotherapy prior to enrollment
  • Known cerebrospinal metastases and other know central nervous system metastases
  • Active or suspected autoimmune disease
  • Known history of primary immunodeficiency
  • Known history of active pulmonary tuberculosis
  • Known history of allogenic organ transplant or hematopoietic stem cell transplant
  • Pregnant

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jessie Solise
Phone Number: 601-984-1963
Email: jsolise@umc.edu
Principal Investigator:Tang, Shou J, M.D.
How to participate in our Clinical Trials